Sirtris pockets $37M in venture funds
Sirtris Pharmaceuticals of Cambridge, MA has gained $37 million in new funding, including $22 million in venture funds and $15 million in venture debt. The third round was led by new investor Bessemer Venture Partners and included Genzyme Ventures, among others. "Adding the expertise of a world class biopharmaceutical organization like Genzyme and the insight of leading investors like Bessemer and QVT further strengthens our ability to develop a new class of drugs to treat diseases of aging," said Christoph Westphal, M.D., Ph.D., CEO of Sirtris.
- read the release
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets